ConforMIS, Inc. has announced it has appointed 30-year business and financial management veteran Peter Traynor as the company’s Chief Financial Officer. Traynor spent 10 years at Genzyme Corporation where he served as the Chief Accounting Officer and most recently as the Senior Vice President of Business Unit Finance. In this role he was responsible for SEC filings, controllership functions, and financial planning and forecasting for Genzyme’s eight global business units. He was also a member of the Global Operating Team and intimately involved in many of Genzyme’s successful acquisitions.
Peter Traynor New CFO at ConforMIS

“We are very pleased to welcome Peter as our CFO at a time when the company is experiencing substantial growth, ” said Philipp Lang, M.D., CEO of ConforMIS, in the November 8, 2012 news release. “We are at a very important and exciting point in the company’s history, and Peter’s past experience is very well suited to helping us achieve our goals of sustained growth and disciplined operating execution.”
“It’s very exciting to join a company that combines such an innovative and broad ranging technology with an exceptionally fast growing product offering, ” said Traynor in the November 8, 2012 news release. “I look forward to joining a superb leadership team and working with them to support the continued growth of the company’s image-based technology platform.”
Traynor earned an M.S. in Finance from Bentley College Graduate School and a B.A. in Accounting from the University of Massachusetts. He is currently completing a G.M.A in International Relations from the Fletcher School of Law and Diplomacy at Tufts University.
Traynor told OTW,
I have joined ConforMIS at a time when our innovative technology and product offering are growing at an extremely high rate. I will be responsible for putting in a financial planning process that can guide the continued growth of our image-based technology platform, while maintaining our investment discipline and controls.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.